Topics

“We were treated fairly by the division of neurology,” Sarepta's CEO said, referring to reviewers within the FDA who turned Vyondys 53 away in August. https://buff.ly/2NpNAl2 

18:00 EST 7 Nov 2019 | STAT

“We were treated fairly by the division of neurology,” Sarepta's CEO said, referring to reviewers within the FDA who turned Vyondys 53 away in August. https://buff.ly/2NpNAl2 

Original Article: “We were treated fairly by the division of neurology,” Sarepta's CEO said, referring to reviewers within the FDA who turned Vyondys 53 away in August. https://buff.ly/2NpNAl2 

NEXT ARTICLE

More From BioPortfolio on "“We were treated fairly by the division of neurology,” Sarepta's CEO said, referring to reviewers within the FDA who turned Vyondys 53 away in August. https://buff.ly/2NpNAl2 "

Quick Search

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...